Walter Jäger


Ao. Univ.
Prof., Mag. pharm., Dr. rer. nat.

Address: Department of Clinical Pharmacy and Diagnostics, University of Vienna
                Althanstrasse 14
                A-1090
Vienna, Austria

Phone: (+43-1)-4277-55576

Fax: (43-1)-4277-9555

E-mail:
walter.jaeger@univie.ac.at
 

Research interests:


Teaching:

 

Publications:

  1.   H.P. Koch, W. Jäger: Selen im Knoblauch und in Knoblauchpräparaten. Dtsch. Apoth. Ztg. 128, 993-995 (1988)
  2. Georgopoulos, M. Czejka, W. Jäger, N. Starzengruber, H. Lackner: High-performance liquid chromatographic determination of teicoplanin in plasma: comparison with a microbiological assay. J. Chromatogr. B 494, 340-346 (1989).
  3. M. Czejka, W. Jäger, J. Schüller: Mitomycin C determination using loop-column extraction: a rapid and sensitive high-performance liquid chromatochraphic assay forpharmacokinetic studies with spherex starch particles. J. Chromatogr. B 497, 336-341 (1989).
  4. H.P. Koch, W. Jäger: Allicin-Freisetzung aus frischem und getrocknetem Knoblauch und     einigen daraus hergestellten Fertigarzneimitteln. Dtsch. Apoth. Ztg.129, 273-276 (1989).
  5.  E. Urban, W. Jäger, H.P. Koch: Modellverbindungen fiir "Garlicin" und ihre antimikrobielle Wirksamkeit im Hefe-Wuchstest. Sci. Pharm. 57, 451-455 (1989). 
  6.  L. Jirovetz, G. Buchbauer, W. Jäger, V. Raverdino, A. Nikiforov: Determination of lavander oil fragrance compounds in blood samples. Fresenius J. Anal. Chem. 338, 922-923 (1990). 
  7. H. Spreitzer, W. Jäger: Bestimmung von Formaldehydspuren in wässrigen Lösungen. Arch. Pharm. 323, 445-446 (1990). 
  8.  H. Spreitzer*, W. Jäger*, M. Grimm, E. Eybl, M. Müller: Glutaraldehydrückstände Herzklappen-transplantaten. Arch. Pharm. 323, 881-882 (1990). 
  9.  H.P. Koch, W. Jäger: Knoblauch-Ölmazerate: analytische Bewertung von Knoblauchzubereitungen in öliger Lösung. Dtsch. Apoth. Ztg., 130, 2469-2474 (1990).
  10. M. Czejka, W. Jäger, H. Lackner, J. Schüller: "loop-column"-Technik: ein einfaches Extraktionsverfahren zur Katecholaminbestimmung aus biologischem Material. Lab. Med. 14, 387-390 (1990). 
  11.  W. Jäger, M. Czejka, J. Schüller, U. Fogl, E. Czejka, H. Lackner: Rapid and simple high-performance liquid chromatographic assay for 5'fluorouracil in plasma for bioavailability studies. J. Chromatogr. B 532, 411-417 (1990). 
  12. M. Czejka, W. Jäger, J. Schüller: Influence of hyaluronidase on the blood plasma levels of 5-fluorouracil in patients. Pharmazie 9, 693-694 (1990). 
  13. M. Czejka, W. Jäger, A. Georgopoulos: Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration. Euro. J. Drug Metabol. Pharmacokin. 15, 219-222 (1990). 
  14. P. Chiba, T. Szekeres, W. Jäger: Determination of Pyrimidine Deoxynucleoside 1-ß-D-Arabinofuranosyl-cytosine Triphosphate. Eur. J. Clin. Chem. Clin. Biochem. 29, 385-389 (1991).
  15. L. Jirovetz, W. Jäger, G. Buchbauer, A. Nikiforov, V. Raverdino: Investigations ofanimal       blood samples after fragrance drug inhalation by gas chromatography/mass spectrometry with chemical ionization and selected ion monitoring. Biol. Mass Spectrom. 20, 80l-803 (1991). 
  16. G. Buchbauer, L. Jirovetz, W. Jäger, H. Dietrich, C. Plank, E. Karamat: Aromatherapy: evidence for sedative effects of the essential oil of lavander after inhalation.. Z. Naturforsch. C, 46,1067-1072 (1991). 
  17. L. Jirovetz, G. Buchbauer, W. Jäger, G. Remberg, V. Raverdino, A. Nikiforov: Zur Untersuchung der Inhaltsstoffe und Wirkungen von Heublumen. Seifen-Öle-Fette-Wachse 117, 252-256 (1991).
  18. L. Jirovetz, G. Buchbauer, W. Jäger, W. Balba: A simple and efficient trapping system for the investigation of exhalation samples. Fresenius Z. Anal.Chem. 340, 785-786 (1991). 
  19. W. Jäger*, M. Czejka, C. Seelos, J. Schüller, U. Fogl: Untersuchungen zur Zerfallskìnetik von Ftorafur. Sci . Pharm. 59, 101-106 (1991).  
  20. M. Czejka, W. Jäger, J. Schüller: Einfluß des Vasokonstriktors Glycylpressin auf die Verfügbarkeit von Mitomycin C. Arch. Pharm. 323, 25-27 (1991) 
  21. M. Czejka, W. Jäger, J. Schüller, A Teherani: Pharmakokinetik von Carboplatin nach intraperitonealer Verabreichung. Arch. Pharm. 324, I 83-184 (1991).
  22. M. Czejka, W. Jäger, J. Schüller, G. Schernthaner: Pharmakokinetik und lokaleVerfügbarkeit von Mitomycin C: Einfluß von Vasokonstriktion und Chemoembolisation.   Arzneimittel Forsch. 41, 260-263 (1991). 
  23. M. Czejka, W. Jäger, J. Schüller, U. Fogl, A. D'Assie, A. Georgopoulos: Bioavailability of folinic acid in serum and red blood cells after i.v. and i.a. administration. Int. J.Exptl.Clin. Chemother. 4, 27-31 (1991). 
  24. M. Czejka, W. Jäger, J. Schüller, G. Schernthaner: Vergleichende Bioverfügbarkeit von 5-Fluorouracil und dem Prodrug Ftorafur nach intraarterieller, intravenöser und peroraler Verabreichung. Pharmazie 46, 587-588 (1991). 
  25. M. Czejka, W. Jäger, J. Schüller, U. Fogl, G. Schernthaner: Pharmakokinetische Aspekte der Kombination von Interferon-a- 2b und Folinsäure mit Fluorouracil. Arzneimittel Forsch. 41, 860-863 (1991) 
  26. M. Czejka, J. Schüller, W. Jäger, U. Fogl, C. Weiss, G. Schernthaner: Improvement of the local bioavailability of 5-fluorouracil I: application of biodegradable microspheres and clinical pharmacokinetics. Int. J. Exptl. Clin. Chemother. 4, 161-165 (1991). 
  27. M. Czejka, J. Schüller, W. Jäger, U. Fogl, C. Weiss, A. Georgopoulos: Improvement of the local bioavailability of 5-fluorouracil II. application of  hyaluronidase and clinical pharmacokinetics. Int. J. Clin. Chemother. 4, 213-217 (1991). 
  28. M. Czejka, W. Jäger, W. Zwölfer, B. Podesser: Loop-column techniqué: a new sample clean-up method for the determination of gallopamil from biological matrix. Fresenius Z. Anal. Chem., 342, 200-20l (1992). 
  29. M. Czejka, W. Jäger, J. Schüller, U. Fogl, C. Weiss, H. Kienzel, A. Georgopoulos: Influence of biogradable microspheres on the local bioavailability of mitomycin after intraarterial administration. Int. J. Exptl. Clin. Chemother. 5, 29-32 (1992). 
  30. J. Schüller, M. Czejka, G. Schernthaner, U. Fogl, W. Jäger, M. Micksche: Influence of interferon-alpha-2b with or without folinic acid on pharmacokinetics of fluorouracil. Semin. Oncol. 19, 93-97 (1992). 
  31. J. Schüller, M. Czejka, G. Schernthaner, M. Wirth, C. Bosse, W. Jäger, M. Micksche: Pharmacokinetic aspects of interferon-alpha-2b after intrahepatic or intraperitoneal administration. Semin Oncol. 19, 98-104 (1992).  
  32. W. Jäger* , G. Buchbauer, L. Jirovetz, L. Böhm, M. Fritze: Percutaneous Absorption of Lavender Oil from a Massage Oil. J. Soc. Cosmet. Chem. 43, 49-54 (1992). 
  33. W. Jäger, H.P. Koch, K. Pfaff:  Standard allicin adsorbates on silicates. Phytother. Res.6,149-151 (1992). 
  34. H.P. Koch, W. Jäger, J. Hysek, B. Körpert: Garlic and onion extracts: in vitro inhibition of adenosine deaminase. Phytother. Res. 6, 50-52 (1992). 
  35. G. Buchbauer, L. Jirovetz, W. Jäger: Passiflora and Lime-blossoms: Motility effects after inhalation of the essential oils and some of the main constituents in animal experiment. Arch. Pharm. 325, 247-248  (1992).
  36. W. Jäger* , G. Buchbauer, L. Jirovetz: Evidence of the sedative effect of neroli oil, citronellal and phenylethyl acetate in mice. J. Ess. Oil Res. 4, 387-394 (1992). 
  37. G. Buchbauer, W. Jäger, L. Jirovetz, F. Meyer, H. Dietrich: Wirkungen von Baldrianöl, Borneol, Isoborneol, Bornylacetat und Isobornylacetat auf die Motilität von Versuchstieren (Mäusen) nach Inhalation. Pharmazie, 47 620-622 (1992). 
  38. H.P. Koch, W. Jäger, U. Groh, G. Plank: In vitro inhibition of adenosine desaminase by flavonoids and related compounds. New insight into the mechanism of action of plant phenolics. Meth. Find. Exp. Clin. Pharmacol. 14, 413-417 (1992).
  39. L. Jirovetz, W. Jäger, H.P. Koch: Investigation of volatile constituents of the essential oil of egyptian garlic (Allium sativum L.) by means of GC-MS and GC-FTIR. Z. Lebensm. Unters. Forsch. 194, 363-365 (1992).
  40. 61. L. Jirovetz, H.P. Koch, W. Jäger, G. Remberg: Investigation of German onion oil by GC-FID, GC-MS and GC-FTIR. Pharmazie 47, 455-456 (1992). 
  41. L. Jirovetz, G. Buchbauer, W. Jäger, A. Woidich, A. Nikiforov: Analyses of fragrance compounds in blood samples of mice by GC-MS, GC-FTIR and GC-AES after inhalation of sandelwood oil. Biomed. Chromatogr. 6,133-134 (1992) 
  42. L. Jirovetz, W. Jäger, G. Remberg, J. Espinosa-Gonzales, R. Morales, A. Woidich, A. Nikiforov: Analysis of the volatiles in the seed oil of Hibiscus sabdariffa (Malvaceae) by means of GC-MS and GC-FTIR. J. Agric. Food Chem. 40, 1186-1 l87 (1992). 
  43. L. Jirovetz, H.P. Koch, W. Jäger, G. Fritz, G. Resl: Purslane (Portulaca oleracea L.): Investigation of the plant constituents by means of chromatographic spectroscopic systems for the control of the described cholesterol reduction. Ernährung/Nutrition l7, 226-227 (1993). 
  44. M. Czejka, W. Jäger, J. Schüller, U. Fogl, C. Weiss, G. Schernthaner: Clinical pharmacokinetics and bioavailability of  5-fluorouracil: influence of the biomodulating agents interferon, dipyridamole and folinic acid alone and in combination. Arzneimittel Forsch. 43, 387-390 (1993).
  45.  M. Czejka, J. Schüller, W. Jäger, U. Fogl, C. Weiss: Influence of different doses of interferon-a-2b on the blood plasma levels of  5-fluorouracil. Euro. J. Drug Metab. Ph. 18, 247-250 (1993). 
  46. W. Jäger*, H.P. Koch: Pharmacokinetics and organ distribution of liposome-encapsulated l-carnitine in rats. Arzneimittel Forsch. 43, 974-977 (1993).
  47. W. Jäger*, H.P. Koch, B. Eisler: Pharmacokinetics and bioavailability of ß-sitosterol in rats. A comparison of three new dosage forms. Pharm. Sci. Commun., 4, 21-27 (1993). 
  48. J. Jirovetz, G. Ecker, W. Jäger, T. Heiss: Untersuchungen des Gehalts verschiedener Zwiebelchargen an Blei, Cadmium, Quecksilber und Selen mittels Atomabsorptions-Spektroskopie. Ernährung/Nutrition 17, 265-266 (1993). 
  49. W. Jäger, M. Hofeneder, E. Urban, H.P. Koch: Zytotoxische Aktivität neuer cyclischer Lactone im "Hefe-Test". Pharmazie 48, 553-554 (1993).
  50. G. Buchbauer, L. Jirovetz, W. Jäger, C. Plank, H. Dietrich: Fragrance compounds and essential oils with sedative effects upon inhalation. J. Pharm. Sci. 82, 660-664 (1993). 
  51. H.P. Koch, W. Jäger, U. Groh, J. Hovie, G. Plank, U. Sedlak: Carbohydrates from garlic bulbs (Allium sativum L.) as inhibitor of adenosine deaminase enzyme activity. Phytother. Res. 7, 387-389 (1993).
  52. W. Jäger*, B. Päsler, G. Buchbauer, P. Chiba: Investigation of cytotoxic effects of 8 norbornane derivatives on 4 human cancer cell lines using the MTT assay. Pharmazie, 50, 619-621 (1995).
  53. M. Spatzenegger, W. Jäger*: Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug. Metab. Rev. 27, 397-417 (1995).
  54. W. Jaeger, L.Z. Benet, L.M. Bornheim*: Inhibition of cyclosporine and tetrahydro-cannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica 26, 275-284 (1996).
  55.  G. Finding, R. Madner, M. Fritzer-Szekeres, G. G. Steger, W. Jäger, T. Szekeres: Modulation of 5-fluorouracil resistance in human colon tumor cell lines by azidothymidine. Oncol. Res. 8, 189-196 (1996).
  56.  M. Spatzenegger, G. Ecker, W. Jäger*: Determination of the new MDR-modifier PFP 6 and its metabolites in human liver microsomes by high-performance liquid chromatography. Biomed. Chromatogr. 10, 127-130 (1996).
  57. E. Vielnascher, M. Spatzenegger, A. Mayrhofer, P. Klinger W. Jäger*: Metabolism of dextromethorphan in human liver microsomes: a rapid HPLC assay to monitor cytochrome P450 2D6 activity. Pharmazie 51, 586-588 (1996). 
  58. W. Jäger*, E. Vielnascher, G. Findenig, R.M. Mader, T. Szekeres: Effect of  3'-azido-3'-deoxythymidine on 5-fluorouracil metabolism in human promyelocytic leukaemia HL-60 cells. Pharm. Sci. 2, 445-447 (1996). 
  59. G. Finding, R. Madner, M. Fritzer-Szekeres, G. G. Steger, W. Jäger, T. Szekeres:Modulation of 5-fluorouracil resistance in human colon tumor cell lines by azidothymidine. Oncol. Res. 8, 189-196 (1996).
  60. W. Jäger*, B. Nasel, C. Nasel, R. Binder, T. Stimpfl. W. Vycudilik: Pharmacokinetic studies of the fragrance compound 1,8-cineol in humans during inhalation. Chem. Senses 21, 477-480 (1996).   
  61. E. Vielnascher, D. Romanova, L. Novotny, T. Szekeres, H.L. Elfort, T. Thalhammer, W. Jäger*: Simultaneous determination of the new anticancer agent amidox and its metabolites in rat bile and plasma by high-performance liquid chromatography. J. Chromatogr. B 696, 267-274 (1997). 
  62. W. Jäger*, O. Winter, B. Halper, A. Salamon, M. Sartori, L. Gajdzik, G. Hamilton, G. Theyer, J. Graf, T.Thalhammer: Modulation of liver canalicular transport processes by the tyrosin-kinase inhibitor genistein: implication of genistein metabolism. Hepatology 26, 1467-1476 (1997).
  63. P. Chiba, B. Tell, W. Jäger, E. Richter, M. Hitzler, G. Ecker: Studies on propafenon-type modulators of multidrug-resistance IV: synthesis and pharmacological activity of 5-hydroxy and 5-benzyloxy derivatives. Arch. Pharm. Med. Chem. 330, 343-347 (1997).
  64. N. Fuchs, W. Jäger, A. Lenhardt, L. Böhm, I. Buchbauer, G. Buchbauer: Systemic absorption of topically applied carvone: Influence of massage technique. J. Soc. Cosmet. Chem. 48, 277-282 (1997). 
  65. K. Jurukamjorn, T. Thalhammer, B. Gollackner, E. Pittenauer, W. Jäger*: Metabolism of roxithromycin in the isolated perfused rat liver. J. Pharm. Pharmacol. 50, 515-519 (1998). 
  66. W. Jäger*, B. Zembsch, P. Wolschann, E. Pittenauer, A.M. Senderowicz, E.A. Sausville, H.H. Selacek, J. Graf, T. Thalhammer: Metabolism of the new anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci. 62, 1861-1873 (1998).
  67. P. Platzer, S. Schaden, T. Thalhammer, G. Hamilton, W. Jäger*: Biotransformation of topotecan in isolated perfused rat liver: identification of three novel metabolites. Anticancer Res. 18, 2695-2700 (1998).
  68. P. Platzer, W. Herzog, T. Thalhammer, G. Hamilton, I. Haberl, W. Jäger*: Formation of a novel topotecan metabolite in the hormone-independent human prostate carcinoma cell lines DU-145 and PC-3. Anticancer Res. 18, 2737-2742 (1998).
  69. W. Jäger*, M. Sartori, W. Herzog, T. Thalhammer: Genistein metabolism in liver microsomes of Wistar and mutant TR--rats. Res. Commun. Mol. Path. 100, 105-116 (1998).
  70. M. Spatzenegger, G. Ecker, W. Jäger*: Metabolism of the new MDR-modifier AM05 by human liver microsomes. Sci. Pharm. 66, 159-168 (1998).
  71. W. Jäger*, M.A. Correia, L.M. Bornheim, A. Mahnke, W.G. Hanstein, L. Xue, L.Z. Benet:     Ethynylestradiol-mediated induction of hepatic CYP3A9 in female rats: implication for cyclosporine metabolism. Drug Metab. Dispos. 27, 1505-1511 (1999). 
  72.  P. Platzer, T. Thalhammer, G. Hamilton, E. Ulsberger, E. Rosenberg, R. Wissiack, W. Jäger*: Metabolism of camptothecin, a potent topoisomerase I inhibitor, in the isolated         perfused rat liver. Cancer Chemother. Pharmacol. 45, 50-54 (2000).
  73. W. Jäger*, M. Mayer, P. Platzer, G. Reznicek, H. Dietrich, G. Buchbauer: Stereoselective metabolism of the monoterpene carvone by rat and human liver microsomes. Pharm. Pharmacol. 52, 191-197 (2000).
  74. Hamwi, A. Salamon, R. Steinbrugger, M. Fritzer-Szekeres, W Jaeger, T. Szekeres      Cyclosporine metabolism in patients after kidney, bone marrow, heart/lung and liver transplantation in the early and late post-transplant period. Am. J. Clin. Pathol. 114, 536-543 (2000).
  75. A.Salamon, E. Vielnascher, B. Hagenauer, T. Szekeres-Fritzer, T. Thalhammer, W. Jäger*: Metabolism of the new ribonucleotide reductase inhibitor amidox in the isolated perfused rat liver. Anticancer Res. 20, 3521-3526 (2000).
  76.  W. Jäger*, M. Mayer, U. Kratzert, G. Reznicek, G. Buchbauer: Percutaneous absorption of the monoterpene carvone: implication of stereoselective metabolism on blood levels. J. Pharm. Pharmacol. 53, 637-642 (2001). 
  77. B. Hagenauer, A. Salamon, T. Thalhammer, O. Kunert, E. Haslinger, P. Klinger, A. M. Senderowicz, E. A. Sauaville, W. Jäger*: In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UGT1A1 and UGT1A9. Drug.Metab.Disp. 29, 191-197 (2001).
  78.  T. Bachel, T.Thalhammer, W. Jäger, P. Haslmayer, B. Alihodzic, S. Bakos, E. Hitchman, A.M. Senderowicz, E. Penner: Characterizaion of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases. Hepatology 33, 1053-1059 (2001).
  79.  Salamon, B. Hagenauer, Thalhammer, T. Szekerez, K. Krohn, H.N. Jayaram, W. Jäger*: Metabolism and disposition of the novel antileukaemic drug, benzamide riboside, in the isolated perfused rat liver. Life Sci. 69, 2489-2502 (2001) 
  80. P. Platzer, T.Thalhammer, G. Reznicek, G. Hamilton, R. Zhang, W. Jäger*: Metabolismand biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver. Int. J. Oncol. 19, 1287-1293 (2001).
  81. G.F. Fischer, I. Fae, D. Mann, D. Kriks, W. Jäger, W. Platzer, W.R. Mayr, B. Volc-Platzer. An HLA class-II allele frequent in Eskimos and Amerindians is found in the Tyrolean Ice Man. Ann. Hum. Genet. 65, 363-9 (2001),
  82. J. Easmon, G. Pürstinger, T. Roth, H.H. Fiebig, M. Jenny, W. Jäger, G. Heinisch, J. Hoffmann: 2-Benzoxazolyl and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine: an novel class of antitumor agents. Int. J. Cancer, 94, 89-96 (2001). 
  83. J. Easmon, G. Pürstinger, G. Heinisch, T. Roth, H.H. Fiebig, W. Holzer, W. Jäger, M. Jenny, J. Hoffmann: Synthesis, cytotoxicity, and antitumor activity of copper (II) and iron (II) complexes of 4 N-azabicyclo[3.2.2]nonane thiosemicarbazones derived from acyl diazines. J. Med. Chem. 44, 2164-2171 (2001).
  84. M. Gaugg, P. Haslmayer, W. Jäger, T.Thalhammer: Influence of hypotonic stress on the biliary excretion of doxorubicin in Wistar and TR-rats. Anticancer. Res. 21, 2745-2752 (2001).
  85. C. Armbruster, G.M. Stiegler, B.V. Vcelar, W. Jäger, N. Michael, N. Vetter, H.W.D. Katinger: Intravenous therapy with two human monoclonal antibodies (hmAbs 2F5, 2G12) against HIV-1: A phase I trial in asymtomatic volunteers. AIDS 16, 227-233 (2002).  
  86. R. Gratzl, G. Sodeck, P. Platzer, W. Jäger, J. Graf, A. Pollak, T. Thalhammer: Treatment of toxoplasmosis in pregrancy: concentrations of spiromycin and neospiramycin in maternal serum and amniotic fluid. Eur. J. Clin. Microbiol. Infect. Dis. 21, 12-16 (2002).
  87. K. Schaufler, P. Haslmayer, W. Jäger, M. Pec, T. Thalhammer: The environmental toxin 2,3,7,8,-tetrachlorodibenzo-p-dioxin induces cytochrome P450 activity inhigh passage PC 3 and DU 145 human prostate cancer cell lines. Int. J. Mol. Med. 9, 411- 416 (2002) 
  88. W. Jäger*, A. Salamon, T. Szekeres: Metabolism of the novel IMP dehydrogenase inhibitor benzamide riboside. Curr. Med. Chem. 9, 781-786 (2002).
  89. M. Fritzer-Szekeres, A. Salamon, M. Grusch, Z. Horvath, T. Höchtl, R. Steinbrugger, W.Jäger, G. Krupitzka, H. L. Elford, T. Szekeres: Trimidox, an inhibitor of  ribonucleotide reductase, synergistically enhances the inhibition of colony formation by Ara-C in HL-60 human promyelocytic leukaemia cells. Biochem. Pharmacol. 64, 481-485 (2002).
  90. U. Neckel, C. Joukhadar, M. Frossard, W. Jäger, M. Müller, B. X. Mayer. Simultaneous determination of levofloxacin and ciprofloxacin in microdialysates and plasma by high-performance liquid chromatography. Anal. Chim. Acta 463, 199-206 (2002).
  91. G. Stiegler, C. Armbruster B. Vcelar, H. Stoiber, R. Kunert, N.L. Michael, L. L. Lagodzinski, C. Ammann, W. Jäger, J. Jacobson, N. Vetter, H. Kattinger: Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymotomatic HIV-1 infected humans: a phase I eveluation. AIDS 16, 2019-2025 (2002).
  92. P. Haslmayer, T. Thalhammer, W. Jäger, S. Aust, G. Steiner, C. Ensinger, P. Obstist: The peroxisome proliferation-activated receptor g ligand 15-deoxy-D12,14-prostaglandin J2 induces vascular endothelial growth factor in the hormone prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637. Int. J. Oncol. 21, 915-920 (2002).
  93. W. Jäger*, E. Gehring, B. Hagenauer, S. Aust, A. Senderowicz, T. Talhammer: Biliary excretion of flavopiridol and ist glucuronides in the isolated perfused rat liver: role of the canalicular multispecific organic anion transporter (cmoat). Life Sci. 73. 2841-2854 (2003).   
  94. W. Jäger*, E. Gehring, B. Hagenauer, S. Aust, A. Senderowicz, T. Thalhammer: The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin impact on therapy. Int. J. Clin. Pharmacol. Ther. 41, 610-611 (2003).
  95. W. Weber, W. Jäger, T. Erker: Synthesis of tricyclic pyridol [2,3-b][1,4]-thiazines via nucleophilic substitution of activated precursors. J. Heterocyclic Chem. 40, 851-854 (2003).
  96. B. Meyer, S. Gendy, G. Karth, G. Locker, G. Heinz, W. Jäger, F. Thalhammer: How to calculate clearance of higly protein-bound drugs during continous venovenous hemofiltration demonstrated with flucloxacillin. Kidney Blood Press Res. 26, 135-140 (2003).
  97. S. Aust, T. Thalhammer, S. Humpeler, W. Jäger, M. Klimpfinger, G. Tucek, P. Obrist, W. Marktl, E. Penner, C. Ekmekcioglu: The melatonin receptor subtype MT1 is expressed in human gallbladder epithelia. J. Pineal Res. 36, 43-48 (2004). 
  98. M. Murias, N. Handler, T. Erker, K. Pleban, G. Ecker P. Saiko, T. Szekeres, W. Jäger*:  Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg. Med. Chem. 12, 5571-5578 (2004).
  99. P. Saiko, Z. Horvath, W. Bauer, T. Hoechtl, M. Grusch, G. Kruitza, P. Rauko, R.M. Mader, W. Jäger, H. Schott, L. Novotny, M. Fritzer-Szekeres, T. Szekeres: In vitro and in vivo antitumor activity of novel amphiphilic dimmers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine. Int. J. Oncol.25, 357-364 (2004).
  100. P. Friedrich, S. Eappen,W. Jäger, E. Schernhammer, A. M. Zizza, G. K. Wang, P. Gerner: Phase Ia and Ib study of antitryptiline for ulnar nerve block in humans: side effects and efficacy. Anesthesiology 100, 511-518 (2004).
  101. V. Fuhrmann, P. Schenk, W. Jäger, S. Ahmed, F. Talhammer: Pharmacokinetics ofmoxifloxacin in patients undergoing continous venovenous haemodiafiltration.  J. Antimicrob. Chemother. 54, 780-784 (2004).
  102. S. Aust, P. Obrist, W. Jäger, M. Klimpfinger, G. Tucek, F. Wrba, E. Penner, T. Thalhammer: Subcellular localization of the ABCG2 transporter in normal and malignant human gallbladder epithelium. Lab Invest. 84, 1024-36 (2004). 
  103. C. Armbruster, G. M.Stiegler, B.A.Vcelar, W. Jäger, U. Koller, R. Jilch, C.G. Ammann, M. Pruenster, H. Stoiber, H. W. Katinger: Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J. Antimicrob. Chemother. 54, 915-920 (2004).
  104. B. Hagenauer, A. Maier-Salamon, Z. Thalhammer, P. Zollner, A. Senderowicz, W. Jäger*: Metabolism of UCN-01 in isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. Oncol. Rep. 11: 1069-1075 (2004).
  105. Z. Horvath, P. Saiko, C. Illmer, S. Madlener, T. Hoechtl, W. Bauer, T. Erker, W. Jäger, M. Fritzer-Szekeres, T. Szekeres: Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Exp Hematol. 33, 329-35 (2005).
  106.  S. Aust, P. Obrist, M. Klimpfinger, G. Tucek, W. Jäger, T. Talhammer: Altered expression of the hormone- and xenobiotic-metabolizing sulfotransferase enzymes 1A2 and 1C1 in malignant breast tissue. Int. J. Oncol. 26, 1079-85 (2005).
  107. M. Murias, W. Jäger*, N. Handler, T. Erker, Z. Horvath, T. Szekeres, H. Nohl, L. Gille: Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem. Pharmacol. 69, 903-12 (2005).
  108. P.Saiko, Z. Horvath, W. Jäger, H. Schott, M. Fritzer-Szekeres, T. Szekeres: Heterodinucleoside phosphates of 5-fluorodeoxyuridine and arabinofuranosylcytosine-new drugs in cancer chemotherapy? In Vivo 19, 205-14 (2005). 
  109. B. Meyer, G. V. Kornek, M. Nikfardjam, G. D. Karth, H. G. Locker, W. Jäger, F. Thalhammer: Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J. Antimicrob. Chemother. 56, 172-9 (2005).
  110. P. Saiko, Z. Horvath, C. Illmer, S. Madlener, W. Bauer, T. Hoechtl, N. Erlach, M. Grusch, G. Krupitza, R. M. Mader, W. Jäger, H. Schott, R. P. Agarwal, M. Fritzer-Szekeres, T. Szekeres: Cytotoxic effects of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine in cross-resistant H9 human lymphoma cells. Leuk. Res. 29, 785-91 (2005).
  111. M. Urpi-Sarda, O. Jauregui, R. M. Lamuela-Raventos, W. Jäger, M. Miksits, M. I. Covas, C. Andres-Lacueva: Uptake of diet resveratrol into the human low-density lipoprotein. Identifcation and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal. Chem. 77: 3149-55 (2005).
  112. F. Thalhammer, A. Maier-Salamon, W. Jäger*: Examination of stability and compatibility of flucloxacillin (Floxapen) and ceftazidime (Fortum) in two infusion media: relevance for the clinical praxis. Wien. Med. Wochenschr. 155, 337-43 (2005).
  113. G. Buchbauer, . Jäger, A. Gruber, H. Dietrich: R-(+)- and S-(-)-Carvone: influence of chirality on locomotion activity in mice. Flavour Fragr. J. 20, 686-689 (2005).
  114. S. Aust, W. Jaeger, M. Klimpfinger, K. Mayer, G. Baravalle, C. Ekmekcioglu, T. Thalhammer: Biotransformation of melatonin in human breast cancer cell lines: Role of sulfotransferase 1A1. J. Pineal Res. 39, 276-82 (2005).
  115.  M. Miksits, A. Maier-Salamon, S. Aust, T. Thalhammer, G. Reznicek, O. Kunert, E. Haslinger, T. Szekeres, W. Jaeger*: Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1. Xenobiotica 35: 1101-1119 (2005)
  116. N. Handler, W. Jaeger, B. Kuen-Krismer, T. Erker: Cyclooxygenase-1 and Cyclooxygenase-2 Inhibition of Novel 1,2-Disubtituated Imidazoles. Arch. Pharm. 338: 602-604 (2005).
  117. H. Halbwith, S. Kahl, W. Jäger, G. Reznicek, G. Forkmann, K. Stich: Synthesis of (14C)- labeled 5 deoxyflavonoids and their application in the study of dihydoflavonol/ leucoanthocyanidin interconversion by dihydroflavonol 4-reductase. Plant Sci. 170: 587-595 (2006).
  118. A. Maier-Salamon, B. Hagenauer, M. Wirth, F. Gabor, T. Szekeres, w. Jäger: Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm. Res. 23: 2107-2115 (2006).
  119. R. Zomora-Ros, M. Urpi-Sarda, R. M. Lamuela-Raventos, R. Estruch, M. Vazquez-Agell, M. Serrano-Martinez, W. Jaeger, C. Andres-Lacueva: Diagnostic performance of  urine resveratrol metabolites as a biomarker of moderate wine consumption. Clin. Chem. 52: 1773-1780 (2006).
  120. B. Benedek, N. Geisz, W. Jäger, T. Thalhammer, B. Kopp: Choleretic effects of yarrow (Archillea millefolium s.l.) in the isolated perfused rat liver. Phytomedicine (in press, 2006).
  121. Z. Horvath, M. Murias, P. Saiko, T. Erker, N. Handler, W. Jaeger, M. Grusch, M. Fritzer-Szekeres, T. Szekeres: Cytotoxic and biochemical effects of 3, 3’,4,4’,5,5’-hexahydroxystilbene, a novel resveratrol analogue in HL-60 human promyelocytic leukaemia cells. Exp. Hematol. (accepted 2006).
  122. R. Zomora-Ros, M. Urpi-Sarda, R. M. Lamuela-Raventos, R. Estruch, M. Vazquez- Agell, M. Serrano-Martinez, W. Jaeger, C. Andres-Lacueva: Diagnostic performance of  urine resveratrol metabolites as a biomarker of moderate wine consumption. Clin.           Chem. 52: 1773-1780 (2006). 
  123. Z. Horvath,.; P. Saiko; C. Illmer; S. Madlener; T. Hoechtl; W. Bauer; T. Erker; W.    Jaeger; M. Fritzer-Szekere; T. Szekeres: Resveratrol, an ingredient of wine, acts synergistically with ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells.Nucleos. Nucleot. Nucl. Acids 25: 1019-1024 (2006). 
  124.  P. Saiko; Z. Horvath; M. Murias; N. Handler; W. Jaeger; T. Erker; M. Fritzer-Szekeres, T. Szekeres: Antitumor effects of 3,3’,4,4’,5,5’-hxahydroxystilbene in HL-60 human promyelocytic leukemia cells. Nucleos. Nucleot. Nucl. Acids 25: 1013-1017 (2006).
  125. M. Urpi-Sarda, R. Zamora-Ros, R. Lamuela-Raventos, A. Cherubini, O. Jauregui, R. Torre, M. Covas, R. Estruch, W. Jaeger, C. Anderes-Lacueva: HPLC-tandem mass spectrometric method to characterize resveratrol metabolism in humans. Clin Chem. 53292-299 (2007). 
  126. P. Saiko, M. Ozsvar-Kozma, S. Madlener, A. Bernhaus, A. Lackner, M. Grusch, Z. Horvath, G. Krupitza, W. Jaeger, K. ammer, M. Fritzer-Szekeres, T. Szekeres: Avemar, a nontoxic fermented wheat germ extract, induces apoptosis and inhibits ribonucleotide reductase in human HL-60 promyelocytic leukemia cells. Cancer Lett. 250: 323-8 (2007) 
  127. L. Gille, W. Stamberg, W. Jäger, G. Reznicek, T. Netscher, T. Rosenau: A new ubiquinone metabolite and its activity at the mitochondrial bc1 complex. Chem Res   Toxicol. 20:591-559 (2007) 
  128. N. Handler, W. Jäger, H. Puschacher, K. Leisser, T. Erker: Synthesis of novel curcumin analogues and their evaluation as selcetive cyclooxygenase-1 (COX-1) inhibitors.      Chem. Pharm. Bull. 55: 64-69 (2007).
  129. N. Handler, G. Brunhofer, C. Studenik, K. Leiser, W. Jaeger, S. Parth, T. Erker: ‘Bridged’ stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg. Med. Chem. 15: 6109-6118 (2007) 
  130. A. Maier-Salamon, B. Hagenauer, G. Reznicek, T. Szekeres, T. Thalhammer, W. Jäger: Metabolism and disposition of resveratrol in the isolated perfused rat liver: role of Mrp2   in the biliary excretion of glucuronides. J. Pharm. Sci (in press, 2007)
  131.  V. Fuhrmann, P. Schenk, W. Jaeger, M. Miksits, N. Kneidinger, J. Warszawska, U. Holzinger, R. Kitzberger, F. Thalhammer: Pharmakokinetics of voriconazol during   continous venovenous hemodiafiltration, J. Antimicrob. Chemother. (accepted 2007). 
  132. P. Saiko, A. Szakmary, W. Jaeger, T. Szekeres: Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutation Res. (in press, 2007) .
  133. P. Saiko, M. Ozsvar-Kozma, A. Bernhaus, M. Jaschke, G. Graser, A. Lackner, M. Grusch, Z. Horvath, S. Madlener, G. Krupitza, N. Handler, T. Erker, W. Jaeger, M. Fritzer-Szekeres, T. Szekeres: N-hydroxy-N’-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: synergistic antitumor activity with arabinofuranosylcytosine. Int. J. Oncol. (in press, 2007).

     

 

Book Chapters

  1. W. Jäger: Pharmakogenetik. In: U. Jaehde, S. Mühlebach, R. Radziwill, W.Schunack (eds.) Lehrbuch der Klinischen Pharmazie. Gustav Fischer, Stuttgart, 72-81 (1998)
  2. W. Jäger: Pharmakogenetik. In: U. Jaehde, S. Mühlebach, R. Radziwill, W.Schunack (eds.) Lehrbuch der Klinischen Pharmazie (2. Auflage). Gustav Fischer, Stuttgart, 97-108 (2003)


Patents

  1. Szekeres, T.; Handler, N.; Jäger, W.; Murias, M.; Erker T. Stilben-Derivate und deren Verwendung in Arzneimitteln. International application No.: PCT/AT 2004/000279. 
  2. Erker, T.; Handler, N.; Jäger, W. Kuen-Krismer, B. Parth S. Cox-II-Inhibitorenverbindungen. International application No.: PCT/AT2005/000374.
  3. Szekeres, T.; Handler, N.; Jäger, W.; Murias, M.; Erker, T. Preparation of stilbens as    cyclooxygenase-2 inhibitors. International application No.: PCT Int. Appl. WO       2005016860  A2  20050224 CAN 142:261298 AN 2005:158620